Product Pipeline

Erectile Dysfunction

Erectile Dysfunction affects over 150 million men worldwide with cases expected to double in 10 years. Most men experience ED at some point in their lives, but 85% of cases are undiagnosed. PDE-5 inhibitors (Viagra®, Levitra®, Cialis®) are the main treatment for ED and generated almost $4.3 billion of sales in 2010. However, up to 40% of men with ED do not respond to PDE-5 monotherapy and patients become less responsive over time. For those who fail PDE-5 inhibitor treatment, the only suitable treatment is a surgical penile implant. Penile erection involves an interaction between the CNS and target tissue. PDE-5s only targets ED through increased peripheral cGMP without an impact on CNS.

Sagene’s combination is the only drug with dual actions targeting CNS and vascular tissue; increasing dopamine in the brain and levels of NO (nitric oxide) and cGMP in target tissue. Based on Sagene’s preclinical studies, selegiline enhances the efficacy of PDE-5 inhibitors at low doses and thus the combination is expected to address many of the current treatment’s shortcomings.